AtriCure, Inc. (NASDAQ:ATRC) Receives Consensus Rating of “Buy” from Analysts

AtriCure, Inc. (NASDAQ:ATRC) has been assigned a consensus recommendation of “Buy” from the nine brokerages that are covering the firm, MarketBeat.com reports. Nine investment analysts have rated the stock with a buy rating. The average 12 month price objective among analysts that have covered the stock in the last year is $42.44.

A number of analysts have recently issued reports on the company. JPMorgan Chase & Co. decreased their target price on AtriCure from $34.00 to $30.00 and set an “overweight” rating for the company in a report on Wednesday, July 31st. Piper Sandler decreased their price objective on shares of AtriCure from $65.00 to $40.00 and set an “overweight” rating for the company in a research note on Wednesday, July 31st. BTIG Research cut their target price on shares of AtriCure from $58.00 to $53.00 and set a “buy” rating on the stock in a research note on Wednesday, July 31st. Needham & Company LLC reduced their target price on shares of AtriCure from $40.00 to $34.00 and set a “buy” rating on the stock in a report on Wednesday, July 31st. Finally, Stifel Nicolaus lowered their price target on AtriCure from $30.00 to $26.00 and set a “buy” rating for the company in a report on Wednesday, July 31st.

AtriCure Stock Down 0.5 %

Shares of ATRC opened at $28.04 on Tuesday. AtriCure has a fifty-two week low of $18.94 and a fifty-two week high of $43.54. The company’s fifty day moving average is $24.98 and its two-hundred day moving average is $24.38. The firm has a market cap of $1.33 billion, a PE ratio of -35.05 and a beta of 1.43. The company has a quick ratio of 2.93, a current ratio of 4.13 and a debt-to-equity ratio of 0.16.

AtriCure (NASDAQ:ATRC) last issued its earnings results on Tuesday, July 30th. The medical device company reported ($0.17) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.17). The firm had revenue of $116.27 million for the quarter, compared to analysts’ expectations of $116.24 million. AtriCure had a negative return on equity of 8.39% and a negative net margin of 9.33%. The firm’s revenue for the quarter was up 15.2% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.12) earnings per share. Analysts forecast that AtriCure will post -0.77 earnings per share for the current year.

Insider Buying and Selling

In other AtriCure news, Director Maggie Yuen sold 3,500 shares of the business’s stock in a transaction on Thursday, August 15th. The shares were sold at an average price of $24.07, for a total value of $84,245.00. Following the transaction, the director now owns 8,970 shares in the company, valued at approximately $215,907.90. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 3.20% of the stock is currently owned by insiders.

Institutional Investors Weigh In On AtriCure

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. boosted its stake in shares of AtriCure by 1.6% during the 4th quarter. Vanguard Group Inc. now owns 4,766,029 shares of the medical device company’s stock valued at $170,100,000 after buying an additional 76,146 shares during the last quarter. Champlain Investment Partners LLC boosted its stake in AtriCure by 27.3% during the 1st quarter. Champlain Investment Partners LLC now owns 2,681,000 shares of the medical device company’s stock valued at $81,556,000 after acquiring an additional 575,605 shares during the last quarter. First Light Asset Management LLC grew its holdings in AtriCure by 42.1% during the 2nd quarter. First Light Asset Management LLC now owns 1,964,703 shares of the medical device company’s stock worth $44,736,000 after acquiring an additional 581,843 shares in the last quarter. Hood River Capital Management LLC acquired a new position in AtriCure during the 2nd quarter worth $40,422,000. Finally, Wellington Management Group LLP increased its position in shares of AtriCure by 7.8% in the 4th quarter. Wellington Management Group LLP now owns 1,329,457 shares of the medical device company’s stock worth $47,448,000 after purchasing an additional 95,824 shares during the last quarter. 99.11% of the stock is currently owned by hedge funds and other institutional investors.

AtriCure Company Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.